Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flamel Technologies makes changes to its board

This article was originally published in Scrip

Executive Summary

Drug delivery company Flamel Technologies has nominated three members to its board of directors: Dr Catherine Bréchignac, Guillaume Cerutti and the Honourable Craig Stapleton. Dr Bréchignac serves as the French Ambassador for science, technology and innovation, and has previously served as a board member of Renault SA. Mr Cerutti is the chairman and CEO of Sotheby's France, as well as a director of Ingenico SA. Ambassador Stapleton was US Ambassador to France from 2005 until 2009 and has served on the board of directors for several companies including Allegheny Properties and Winston Partners.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts